Trump Budget Would Slash Funding For Health, International Organisations 13/02/2018 by William New, Intellectual Property Watch 1 Comment The Trump administration this week proposed drastic cuts in funding for international activities including foreign policy and global health in 2019, while further building up military and big business activities. Programs related to international activities will have to prove their value to American interests and other countries are demanded to pay more, according to the proposed budget sent yesterday to Congress, which is ultimately expected to set about the task of restoring numerous programs.
US May Extend Its Patent Damages Worldwide 09/02/2018 by Steven Seidenberg for Intellectual Property Watch 1 Comment On January 12, the US Supreme Court agreed to hear a case that could produce a major change in US patent law, with effects reaching far beyond America’s borders. At issue in WesternGeco LLC v. ION Geophysical Corp. is whether and when a US patent owner can collect infringement damages on a global basis.
US Industry Index Makes Case For Strong IP Protection Worldwide 09/02/2018 by William New, Intellectual Property Watch 4 Comments The United States Chamber of Commerce sixth annual International IP Index, released yesterday, highlights positive developments in 50 economies to better protect intellectual property rights so as to reward creativity and innovation. But it also takes aim at practices the US industry group still sees as counterproductive.
On IPR, Major US Trading Partners In Firing Line Of US Industry, While Cancer Patients Ask For Access 09/02/2018 by Catherine Saez, Intellectual Property Watch 1 Comment Every year at this time, the Office of the United States Trade Representative collects comments from stakeholders for its review of how well US trading partners are behaving when it comes to protecting and enforcing the intellectual property rights of US companies. Pharmaceutical companies and an alliance of rights holding industries came prepared with a list of countries to be put on special watch lists, including Canada, Brazil, India, Malaysia, and Switzerland. A patient group, on the other hand, asked that trade interests not supersede access to medicines worldwide.
Call For Applications – African Women Entrepreneurship Cooperative 08/02/2018 by Intellectual Property Watch Leave a Comment Are you an African woman entrepreneur seeking to advance your leadership, strategy, and business management skills? Are you interested in connecting with other women business owners from across the continent and being coached by a mentor?
A Brief Sketch Of Privilegio In The Venetian Renaissance 07/02/2018 by Intellectual Property Watch 2 Comments Gavin Keeney writes: As a type of historical morality tale, especially given arguments currently before the European Commission regarding copyright reform and “neighboring rights,” this short treatise addresses the origins of copyright in the Venetian Renaissance in the late 1400s under the aegis of privilegio, notably first granted to authors (author-publishers) versus printers (printer-publishers). Subsequently, printers as publishers would command the lion’s share of such rights to works. Arguably, Venetian privilege transferred the immemorial aspect of written works (here considered “moral rights” for works) to authors in a casual, yet emphatic manner leading to modern copyright. With contemporary copyright nominally belonging to authors, but in fact belonging by expropriation to presses and platforms, it is likely that one of the few solutions, short of benevolent presses fully sharing rights with authors, is for moral rights to return to works by way of the author renouncing copyright but refusing the arrogation of such renounced rights to presses and platforms.
Leaked Letter Shows Pressure On Colombia Not To Issue Compulsory Licence For Glivec 06/02/2018 by William New, Intellectual Property Watch 1 Comment A newly leaked 2016 letter from the CEO of Novartis to the president of Colombia, made available by Swiss group Public Eye, shows the level of concern the Swiss pharmaceutical company had over the effect of possible issuance of a compulsory licence for Novartis drug Glivec in the pivotal South American economy.
Medicines Innovation And Access: Swiss Stimulate New Thinking 06/02/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment BERN, Switzerland — What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need.
Andrei Iancu Named US Patent And Trademark Office Director 06/02/2018 by Dugie Standeford for Intellectual Property Watch 3 Comments By a vote of 94-0, the United States Senate on 5 February confirmed California intellectual property litigator Andrei Iancu as next director of the US Patent and Trademark Office (USPTO). The new Under Secretary of Commerce for Intellectual Property is currently managing partner of Irell & Manella LLP’s Los Angeles firm. The patent and trademark communities wished Iancu luck but said there are many issues at the agency that need his attention.
Biosimilar Industry Launches Information Campaign For Better Acceptance 05/02/2018 by Intellectual Property Watch 1 Comment The International Generic and Biosimilar medicines Association has launched an information campaign on biosimilar medicines in order to raise worldwide understanding and acceptance of biosimilar medicines.